Sign In

Login

Password

Forgot Password ? Sign Up

Nebivolol (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nebivolol" in Indonesian language version.

refsWebsite
Global rank Indonesian rank
31nih.gov
4th place
13th place
26doi.org
2nd place
4th place
10semanticscholar.org
11th place
330th place
3drugbank.com
low place
low place
2drugs.com
399th place
480th place
2web.archive.org
1st place
1st place
2fda.gov
447th place
792nd place
1books.google.com
3rd place
6th place
1worldcat.org
5th place
7th place
1webmd.com
1,169th place
842nd place
1frx.com
low place
low place
1zenodo.org
621st place
1,261st place
1rxabbvie.com
low place
low place
1chemspider.com
8,573rd place
low place

books.google.com (Global: 3rd place; Indonesian: 6th place)

chemspider.com (Global: 8,573rd place; Indonesian: low place)

  • "C22H25F2NO4". ChemSpider. 10 June 2024. Diakses tanggal 10 July 2025.

doi.org (Global: 2nd place; Indonesian: 4th place)

drugbank.com (Global: low place; Indonesian: low place)

go.drugbank.com

  • "Nebivolol". go.drugbank.com. Diakses tanggal 2022-08-17.
  • "DrugBank Nebivolol". go.drugbank.com. Diakses tanggal 2022-08-17.
  • "Nebivolol: Uses, Interactions, Mechanism of Action". DrugBank Online. 17 December 2007. Diakses tanggal 10 July 2025.

drugs.com (Global: 399th place; Indonesian: 480th place)

fda.gov (Global: 447th place; Indonesian: 792nd place)

accessdata.fda.gov

fda.gov

  • Thomas Abrams (28 August 2008). "Warning Letter" (PDF). Food and Drug Administration. Diarsipkan dari asli (PDF) tanggal 28 April 2017. Diakses tanggal 16 December 2019. FDA is not aware of any substantial evidence or substantial clinical experience that demonstrates that Bystolic represents a 'novel' or 'next generation' beta blocker for the treatment of hypertension. Indeed, we are not aware of any well-designed trials comparing Bystolic to other β-blockers. Furthermore, FDA is not aware of any data that would render Bystolic's mechanism of action 'unique.'

frx.com (Global: low place; Indonesian: low place)

nih.gov (Global: 4th place; Indonesian: 13th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

rxabbvie.com (Global: low place; Indonesian: low place)

semanticscholar.org (Global: 11th place; Indonesian: 330th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; Indonesian: 1st place)

  • "Prescribing information for Bystolic". Forest Laboratories, Inc. Diarsipkan dari asli (PDF) tanggal 25 March 2016. Diakses tanggal 11 June 2009.
  • Thomas Abrams (28 August 2008). "Warning Letter" (PDF). Food and Drug Administration. Diarsipkan dari asli (PDF) tanggal 28 April 2017. Diakses tanggal 16 December 2019. FDA is not aware of any substantial evidence or substantial clinical experience that demonstrates that Bystolic represents a 'novel' or 'next generation' beta blocker for the treatment of hypertension. Indeed, we are not aware of any well-designed trials comparing Bystolic to other β-blockers. Furthermore, FDA is not aware of any data that would render Bystolic's mechanism of action 'unique.'

webmd.com (Global: 1,169th place; Indonesian: 842nd place)

worldcat.org (Global: 5th place; Indonesian: 7th place)

search.worldcat.org

  • National Heart Foundation of Australia. National Blood Pressure and Vascular DiseaseAdvisory Committee (2016). Guideline for the diagnosis and management of hypertension in adults. Melbourne, Vic. ISBN 978-1-74345-110-6. OCLC 970693159. Pemeliharaan CS1: Lokasi tanpa penerbit (link)

zenodo.org (Global: 621st place; Indonesian: 1,261st place)